Anest. intenziv. Med. 2006;17(1):6-13
Antifibrinolytic agents in off-pump cardiac surgery: analysis of blood loss, safety and cost-effectivenessAnaesthesiology - Original Paper
- 1 Kardiochirurgická klinika, Univerzita Karlova, 3. LF a FNKV, Praha
- 2 Oddělení biostatistiky a informatiky, SZÚ, Praha
Objective:
To compare the haemostatic effects of fibrinolytic inhibitors (tranexamic acid, aprotinin) vs. placebo in off-pump coronary artery bypass surgery and to evaluate the impact of this therapy on cost-effectiveness.
Design:
Prospective, randomized, double-blind study.
Setting:
University Teaching Hospital, Prague, Czech Republic.
Material and Method:
100 patients were enrolled in the study and 91 of them were assessed (group A, n = 32, tranexamic acid 1 g before skin incision followed by continuous infusion at 200 mg/h; group B, n = 29, aprotinin 1,000,000 IU before skin incision and 250,000 IU/h afterwards; group C, n = 30, placebo).
Results:
Highly significant inter-group differences were found in the cumulative blood loss within 4 h (geometric means [95% confidence intervals] - group A: 89.3 [72.7, 109.8] mL, group B: 72.3 [49.2, 106.3] mL and group C: 192.3 [151.8, 243.5] mL) (P < 0.001), within 8 h (group A: 152.1 [120.7, 191.6] mL, group B: 130.3 [88.1, 192.8] mL and group C: 283.8 [226.0, 356.3] mL) (P = 0.001), and within 24 h postoperatively (group A: 410.3 [337.6, 498.6] mL, group B: 345.8 [256.0, 398.2] mL and group C: 619.8 [524.3, 732.8] mL) (P < 0.001). At all time points, group C (placebo) was significantly distinct from the groups treated with fibrinolytic inhibitors (groups A, B). However, no essential differences between groups A and B were found. Treated groups did not demonstrate postoperative increase in mean levels of myocardial enzymes compared with group C. No statistically significant inter-group difference was found in the number of re-transfused patients (either packed red blood cells, P = 0.119, or fresh-frozen plasma, P = 0.118) during the first 24 h postoperatively, but the number of re-transfused patients during the hospital stay was statistically significantly higher in group C compared with group B (P = 0.002). Cost effectiveness of the antifibrinolytic agent and blood product treatment seems to be on average the most favourable in the tranexamic acid group.
Conclusion:
Both tranexamic acid and aprotinin seem to be similarly effective in the reduction of postoperative blood loss in off-pump cardiac surgery. Tranexamic acid appears to be a cost-effective and safe alternative to aprotinin.
Keywords: tranexamic acid; aprotinin; cardiac surgical procedures; off-pump coronary artery bypass
Published: February 1, 2006 Show citation
References
- Nuttall, G. A., Oliver, W. C., Santrach, P. J. et. al. Efficiacy of a simple intraoperative transfusion algorithm for non-erythrocyte component utilization after cardiopulmonary bypass. Anaesthesiology, 2001, 94, p. 773-781.
Go to original source...
Go to PubMed...
- Despotis, G. J., Filos, K. S., Zoys, T. N., Hogue, C. W., Jr., Spitznagel, E., Lappas, D. G. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariete analysis in cardiac surgical patients. Anesth. Analg., 1996, 82, p. 13-21.
Go to original source...
Go to PubMed...
- Biglioli, P., Cannata, A., Alamanni, F. et. al. Biological effects of off-pump vs. on-pump coronary artery surgery: focus on inflammation, hemostasis and oxidative stress. Eur. J. Cardio-thoracic Surg., 2003, 24, p. 260-269.
Go to original source...
Go to PubMed...
- Cvachovec, K., Horáček, M., Vislocký, I. A retrospective survey of fibrinolysis as an indicator of poor outcome after cardiopulmonary bypass and a possible early sign of systemic inflammation syndrome. Eur. J. Anaesthesiol., 2000, 17, p. 173-176.
Go to original source...
Go to PubMed...
- Levi, M., Cromheecke, M. E., de Jonge, E. et. al. Pharmacological strategies to decrease blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet, 1999, 354, p. 1940-1947.
Go to original source...
Go to PubMed...
- Alderman, E. L., Levy, J. H., Rich, J. B. et. al. Analyses of coronary graft patency after aprotinin use: results from the international multicenter aprotinin graft patency experience (IMAGE) trial. J. Thorac. Cardiovasc. Surg., 1998, 116, p. 716-730.
Go to original source...
Go to PubMed...
- Casati, V., Gerly, Ch., Franco, A. et. al. Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study. Ann. Thorac. Surg., 2001, 72, p. 470-475.
Go to original source...
Go to PubMed...
- Englberger, L., Markart, P., Eckstein, F. S., Immer, F. F., Berdat, P. A., Carrel, T. P. Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery. Eur. J. Cardio-thorac. Surg., 2002, 22, p. 545-551.
Go to original source...
Go to PubMed...
- Jareš, M., Vaněk, T., Straka, Z., Brůček, P. Tranexamic acid reduces bleeding after off-pump coronary artery bypass grafting. J. Cardiovasc. Surg. (Torino), 2003, 44, p. 205-208.
Go to PubMed...
- Casati, V., Della Valle, P., Benussi, S. et. al. Effects of tranexamic acid in postoperative bleeding and related hematological variables in coronary surgery: a comparison between on-pump and off-pump techniques. J. Thorac. Cardiovasc. Surg., 2004, 128, p. 83-91.
Go to original source...
Go to PubMed...
- Vaněk, T., Brůček, P., Straka, Z. Fast track as a routine for open-heart surgery. Eur. J. Cardio-thorac. Surg., 2001, 21, p. 369-370.
Go to original source...
Go to PubMed...
- Vaněk, T., Jareš, M., Fajt R. et. al. Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). Eur. J. Cardio-thorac. Surg., 2005, 28, p. 563-568.
Go to original source...
Go to PubMed...
- Hekmat, K., Zimmermann, T., Kampe, S. et. al. Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomized, double-blind trial. Curr. Med. Res. Opin., 2004, 20, p. 121-126.
Go to original source...
Go to PubMed...
- Green, J. A., Reynolds, P. S., Makhoul, K. et. al. Potential financial savings of a "bloodless" cardiac surgery initiative. Anesth. Analg., 2003, 96, Abstracts SCA 17.
Go to PubMed...
- Robinson, D., Bliss, E. A model of direct and indirect effects of aprotinin administration on the overall costs of coronary revascularization surgery in a university teaching hospital cardiothoracic unit. Clin. Ther., 2002, 24, p. 1677-1689.
Go to original source...
Go to PubMed...